- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00252356
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (ORION)
March 10, 2009 updated by: Sanofi
An Eight-Week, Double-Blind, Placebo Controlled, Multicenter Study With Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With MDD
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
The study is a multicenter, US and Canadian, randomized, double-blind, 3-parallel-group, placebo- and escitalopram-controlled, Phase III study consisting of four segments (A, B, C and D).
Segment A is a 1-week, placebo, single-blind period.
Segment B is an 8-week, double-blind period.
Segment C is an optional 18-week double-blind extension period.
Segment D is a 1-week safety follow-up period after study drug discontinuation or early termination (during Segment B or C).
Study Overview
Detailed Description
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
The present study is an 8-week, double-blind, placebo- and escitalopram-controlled, randomized, parallel-group study.
A 1-week, placebo, single-blind period precedes the 8-week randomized treatment period and an optional 18-week, double-blind extension period follows the randomized treatment period.
A Safety Follow up Visit is scheduled 1 week after the acute and extension period, or early termination.
Escitalopram, a selective serotonin reuptake inhibitor (SSRI), an approved treatment for MDD, is chosen as a positive control agent in this study.
The dose of 10 mg is within the approved dose range with no need for dose adjustment in elderly patients.
This trial is designed to formally compare the efficacy, safety, and tolerability of SR58611A to placebo.
Escitalopram is used as a positive control.
Study Type
Interventional
Enrollment (Actual)
468
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Laval, Canada
- Sanofi-Aventis Administrative Office
-
-
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Main inclusion criteria:
- 1. Out-patients, 18 year and older.
- 2. Major Depressive Disorder (MDD) with a recurrentMajor Depressive Episode (MDE) according to DSMIV-TR criteria
- 3. Duration of current episode is at least of 6 weeksunless severity of symptoms justifies shorter duration.
- 4. Patients have been treated or hospitalized for aprevious episode, or a previous episode requiredantidepressant treatment(s) at the recommended doselevel for a continuous total duration of at least 2months.
Exclusion Criteria:
Main exclusion criteria:
- 1. Patients at immediate risk for suicidal behavior
- 2. Patients with a MDE with psychotic features, catatonic features, seasonal pattern or postpartum onset
- 3. The duration of the current depressive episode is greater than 2 years
- 4. Patients whose current depressive episode is secondary to a general medical condition
- 5. Patients with a lifetime history of (1) bipolar disorder, (2) psychotic disorder, (3) antisocial personality disorder
- 6. Patients who have received non-pharmacologic, somatic treatments for psychiatric disease
- 7. Patients who have initiated, stopped, or changed the frequency or nature of psychotherapy within 3 months prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
17-item Hamilton Depression Rating Scale (HAM-D) total score
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety assessments
|
Change from baseline in Clinical Global Impression (CGI) and MADRS Severity of Illness score
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
November 10, 2005
First Submitted That Met QC Criteria
November 10, 2005
First Posted (Estimate)
November 11, 2005
Study Record Updates
Last Update Posted (Estimate)
March 12, 2009
Last Update Submitted That Met QC Criteria
March 10, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFC5041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on SR58611A
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedAtopic DermatitisUnited States, Canada, Germany, Japan
-
SanofiCompletedMajor Depressive DisordersRussian Federation, Spain, Singapore, Taiwan, Tunisia, Argentina, Chile, Hong Kong, Morocco, South Africa, Greece
-
SanofiCompletedDepressive DisorderRomania, Bulgaria, Serbia, Slovakia, Finland
-
SanofiTerminatedAnxiety DisordersFrance, Russian Federation, Australia, Germany, Spain, Mexico, Hungary, Italy, Chile
-
SanofiCompletedAnxiety DisorderUnited States
-
SanofiCompletedDepressive Disorder | Major DepressionFrance, Poland, Romania, Russian Federation, Bulgaria, Serbia, Slovakia, Czech Republic, Mexico, Argentina, Croatia, Finland, South Africa
-
SanofiCompletedMajor Depressive DisorderUnited States
-
SanofiCompletedMajor Depressive DisorderUnited States, Canada
-
SanofiTerminatedAnxiety DisordersRomania, Slovakia, Croatia, Austria, Finland
-
SanofiCompletedAnxiety DisordersFrance, Russian Federation, Sweden, Estonia, Argentina, Austria, South Africa